Celltrion Settlement Puts Prolia And Xgeva Biosimilars On Ice – But Only Until June
Korean Firm Yet To Receive FDA Approvals Following November 2023 Filings
Celltrion has shaken hands with Amgen on a settlement agreement for its proposed US rivals to Prolia/Xgeva, as it continues to await approval from the US FDA for its biosimilar denosumab candidates.
